Severe ObesitySCANNCT07280845
Longitudinal Retrospective Analysis of Prospectively Collected Data for Outcomes After Primary Sleeve Gastrectomy (N=20 000) in the Swedish National Quality Registry SOReg (Scandinavian Obesity Surgery Registry)
An observational study of Severe Obesity and Sleeve Gastrectomy, run by Linkoeping University at 1 site in Sweden.
Trial summary
The main questions to answer are: Weight outcomes in weight strata over time? What was the proportion of patients reaching sufficient weight outcome in different weight strata? To what extent are co-morbid conditions improved or put in remission? What is the risk of experience a complication? What was the proportion… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Severe Obesity, Sleeve Gastrectomy
- How many people
- 19,977 participants
- Where
- 1 siteSweden
- Study dates
- 1 Jan 2012to 31 Oct 2024
- How long will I take part?
- 15 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients in Sweden operated with the bariatric techniqu sleeve gastrectomy between 1 Jan 2012 and 31 of Oct 2024
Who may be able to join
- All patients undergoing sleeve gastrectomy in Sweden from 1 Jan 2012
- Being registered in the national quality register SOReg
Who cannot join
- Previously undergone bariatric surgery
- Sleeve gastrectomy as a planned two staged intervention
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Long-term Outcomes After Primary Sleeve Gastrectomy in the Swedish Scandinavian Obesity Surgery Registry (SCAN - Sleeve Cohort Analysis on a National Level)
The main questions to answer are:
- Weight outcomes in weight strata over time?
- What was the proportion of patients reaching sufficient weight outcome in different weight strata?
- To what extent are co-morbid conditions improved or put in remission?
- What is the risk of experience a complication?
- What was the proportion of patients converted to another bariatric procedure?
- What us the reason for conversion?
Participants already undergone bariatric surgery as part of their regular medical care for severe obesity and only registry data will be analyzed.
Read the detailed description
Few countries have a national quality registry for metabolic and bariatric surgery with a very high coverage and level of adherence. The national registry database in Sweden - SOReg -was founded in 2007 and since 2012 close to 100% of all metabolic and bariatric surgery in Sweden is captured, and all active clinics report to the registry [18]. Thus, SOReg data represents a unique opportunity to report the long-term outcomes of the sleeve gastrectomy on a national level and to correlate preoperative demographics, operating unit and procedural factors with weight loss outcomes, resolution of comorbidities and complications. It also provides us insight into the true prevalence of conversion of sleeve gastrectomy to another procedure and the reasons hereto.
Primary aim:
The primary aim of the SCAN study is to evaluate the surgical outcomes (weight loss, resolution of comorbidities and complications) of the sleeve gastrectomy in a national cohort with a long-term follow-up. Weight outcomes will be presented in weight strata.
The secondary aims are:
For the whole cohort:
- Description of anthropometrics prior to sleeve gastrectomy.
- Determining rate of self-paying vs publicly funded procedures.
- Description of procedural factors
- To evaluate possible correlations in preoperative demographics, operating unit and procedural factors with outcomes.
- Estimate the prevalence of conversion of sleeve gastrectomy to another procedure (RYGB, DS, SASI etc) at different follow-up times, as well as determining the indications that lead to conversion.
- Identifying the rate of hiatal hernia in the whole cohort (n=20435) as plotted against time (baseline= before the sleeve procedure, thereafter yearly).
- Identifying the rate of clinical dyspepsia in the whole cohort (n=20435) as plotted against time (baseline= before the sleeve procedure, thereafter yearly).
- Identifying the Incidence of initial suboptimal clinical response vs recurrent weight gain in the whole cohort versus the group of patients converted regardless of indication for conversion.
- Estimate eligibility for a second revisional procedure in the total cohort due to either suboptimal weight loss outcomes/recurrence of comorbidities or dyspepsia.
- Identifying potential predictors for incidence of clinical dyspepsia ("Time from sleeve operation to dyspepsia is the outcome") leading to conversion (use of PPI before sleeve, dyspepsia before sleeve, hiatal hernia before sleeve, age, sex, BMI, smoking status, and clinical operating unit (high-volume vs low-volume). Nb! Dyspepsia is noted yearly (column HQ: year one; IV: year two etc).
Study Design The study is a retrospective study on prospectively collected data from the national registry on bariatric surgery, SOReg, where data on metabolic and bariatric surgeries in Sweden are collected.
The cohort will be all primary sleeve operations in Sweden performed during the years 2012 to 2024, with a total of n=20.435 patients. TThe design will be register-based cohort study, with a maximum follow-up time up to 15 years.
Study outcomes and predictors in weight strata (5 BMI points each)
a Conversion: Prevalence of conversion of SG to another procedure: RYGB, SASI, Duodenal switch, or a two-stage planned procedure (first SG and then later another like the DS). The data from the excel file should be held up against the total number of sleeve procedures in the same time period to assess the true prevalence.
b Procedural factors: These include operative time, Length of Stay (LOS), early complications (leaks, bleeding, reoperation, non-operative intervention, readmission, cardiac events, pneumonia, thromboembolic complications, wound infection, sepsis, death), and late complications (bowel obstruction, marginal ulcers, abdominal pain, laparoscopy with no pathology, malnutrition, and malabsorption)
c Predictors for all complications en bloc, for mortality, for early vs late complications, and then for all complications individually. Potential variables to be evaluated: Height, weight, sex, BMI, medical comorbidities one-by-one, smoking status, operative time, prior thromboembolic complications, operating unit (high-volume vs low-volume as defined by the number of procedures the operating units perform annually; this information is not available from the excel file, but I suggest preliminarily that the number of complications are stratified according to the respective operating units)
e Predictors for resolution of symptoms: intestinal limb length (alimentary limb, biliopancreatic limb and common channel), crura plasty (posterior vs anterior), other concomitant reflux procedures, operating unit (high-volume vs low-volume).
f Weight loss outcomes weight in kg, body mass index (BMI), percent of total weight loss (%TWL), percent excess weight loss (%EWL), and delta BMI (ΔBMI). The above mentioned are calculated as follows:
- %TWL = (Initial Weight - Postop Weight)/ (Initial Weight x 100)
- %EWL = (Initial Weight - (Postop Weight) / (Initial Weight - Ideal Weight)
- ΔBMI = (Initial BMI - Postop BMI) (Ideal weight is defined as the weight in kg that corresponds to a BMI of 25 kg/m2) g Medical comorbidities Diabetes mellitus (DM), Hypertension (HT), Dyslipidaemia (DL), and Obstructive Sleep Apnoea (OSA) i Weight loss outcomes (BMI, kg, EWL and TWL) should be assessed for Group 1 as a whole and also when dichotomized according to the following two groups: I) Recurrent weight gain (previously called poor responders) II) Initial suboptimal clinical response (previously called non-responders). j Eligibility here is defined as having a BMI ≥ 35 kg/m2 or BMI ≥ 30 kg/m2 along with a recurrence/presence of obesity-associated medical comorbidities (DM, HT, DL, OSA, Arthritis).
Predictors of resolution of comorbidities Variables to be considered potential predictors: preoperative weight and BMI, sex, age, smoking status, distance from angle of Hiss, distance to pylorus, numbers of staplers used, summated length of staplers, operative time.
**Complications: Peri-operative complications: Injury to sleen, bowel perforation, other complication and bleeding (100-499, 500-1500, and >1500 ml).
Complications within 6 weeks: Leakage, Bleeding Abcess/deep infection, Wound dehiscence, Other WOund complication, bowel obstruction/paralysis, Port related complication, Stricture, Ulcer, Cardio-vascular complication, DVT/PE, Pulmonary complication, Unrinary tract infection, Other complication, and Severity of complications according to Clavien Dindo classification.
Complications until 1y:
Complications can then be analysed yearly according to the data available in the spread sheet.
Reasons for conversion to another bariatric procedure and relief of problems:
Group 1: Symptoms: Clinical GERD, dyspepsia, dysphagia, stricture or obstruction, nausea or vomiting, staple line leak, hiatal hernia, intrathoracic migration of the sleeve or anything else that can be classified as complications after a sleeve gastrectomy.
Group 2: Suboptimal weight loss: Initial suboptimal clinical response and recurrent weight gain, as well as recurrence of obesity-associated medical comorbidities or persistent obesity-associated medical comorbidities.
Statistical analyses
Summary tables (descriptive statistics and frequency tables) will be provided for all baseline variables, outcome variables, and safety variables, as appropriate. Continuous variables will be summarized with descriptive statistics (n, mean, standard deviation, range, and median). Frequency counts and percentage of subjects within each category will be provided for categorical data.
For the primary aim, time to first ever conversion will be evaluated with the Kaplan-Meier estimates and Cox proportional hazards models. Time to event will be calculated as the time difference between the index operation with SG to another procedure. Persons without another procedure will be censored at the the time point when the register was complete. From the Kaplan-Meier and Cox-models, cumulative incidence of proportion converting will be evaluated since the time of primary SG operation.
For persons with symptoms leading to conversion, resolution of these symptoms will be evaluated at x months/years since conversion. Time-to-event or logistic regression models.
For persons with suboptimal weight loss as reason for conversion, weight loss outcomes will be evaluated.
Proportions with resolution of co-morbidities and incidence of complications will be analysed with time-to-event/logistic regression model.
- Conditions
- Severe Obesity, Sleeve Gastrectomy
- Keywords
- Sleeve, Sleeve gastrectomy, obesity, longitudinal study, national quality registry
- Medical subject headings
- Obesity, Morbid, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with severe obesity undergoing primary sleeve gastrectomy in Sweden | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Weight loss
BMI loss in strata of 5 BMI units
Measured: 15 years
Weight loss in BMI strata
Measured: 15 years
Weight loss
Various definitions of weight loss over time
Measured: Up to 15 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Dec 2025
- Study start1 Jan 2012
- Primary completion31 Dec 2023
- Study completion31 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Severe ObesityStudies of the same condition, open and under way.
- More trials run by Linkoeping UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 19,977 participants (actual)
- Target duration
- 15 Years
Sponsor and investigators
- Lead sponsor
- Linkoeping University
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Torsten Olbers, Linkoeping University
- Investigators
- Torsten Olbers, MD, Professor, Study chair, Linköpings universitet, 202100-3096
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07280845
- Sponsor's protocol ID
- EPM: 2023-07198-01
- Acronym
- SCAN
- Status last verified
- Dec 2025
- First submitted
- 1 Dec 2025
- Last updated
- 12 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Ongoing further investigations in the dataset
Study at a glance
From the registry record, last updated by the sponsor on 12 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-term Outcomes After Primary Sleeve Gastrectomy in the Swedish Scandinavian Obesity Surgery Registry (SCAN - Sleeve Cohort Analysis on a National Level)
- ClinicalTrials.gov ID
- NCT07280845
- Acronym / sponsor ID
- SCAN / EPM: 2023-07198-01
- Conditions
- Severe Obesity, Sleeve Gastrectomy
- Keywords
- Sleeve, Sleeve gastrectomy, obesity, longitudinal study, national quality registry
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 19,977 participants (actual)
- Lead sponsor
- Linkoeping UniversityOther government
- Study start
- 1 Jan 2012 (actual)
- Primary completion
- 31 Dec 2023 (actual)
- Study completion
- 31 Oct 2024 (actual)
- First posted
- 12 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main questions to answer are:
- Weight outcomes in weight strata over time?
- What was the proportion of patients reaching sufficient weight outcome in different weight strata?
- To what extent are co-morbid conditions improved or put in remission?
- What is the risk of experience a complication?
- What was the proportion of patients converted to another bariatric procedure?
- What us the reason for conversion?
Participants already undergone bariatric surgery as part of their regular medical care for severe obesity and only registry data will be analyzed.
Detailed description
Few countries have a national quality registry for metabolic and bariatric surgery with a very high coverage and level of adherence. The national registry database in Sweden - SOReg -was founded in 2007 and since 2012 close to 100% of all metabolic and bariatric surgery in Sweden is captured, and all active clinics report to the registry [18]. Thus, SOReg data represents a unique opportunity to report the long-term outcomes of the sleeve gastrectomy on a national level and to correlate preoperative demographics, operating unit and procedural factors with weight loss outcomes, resolution of comorbidities and complications. It also provides us insight into the true prevalence of conversion of sleeve gastrectomy to another procedure and the reasons hereto.
Primary aim:
The primary aim of the SCAN study is to evaluate the surgical outcomes (weight loss, resolution of comorbidities and complications) of the sleeve gastrectomy in a national cohort with a long-term follow-up. Weight outcomes will be presented in weight strata.
The secondary aims are:
For the whole cohort:
- Description of anthropometrics prior to sleeve gastrectomy.
- Determining rate of self-paying vs publicly funded procedures.
- Description of procedural factors
- To evaluate possible correlations in preoperative demographics, operating unit and procedural factors with outcomes.
- Estimate the prevalence of conversion of sleeve gastrectomy to another procedure (RYGB, DS, SASI etc) at different follow-up times, as well as determining the indications that lead to conversion.
- Identifying the rate of hiatal hernia in the whole cohort (n=20435) as plotted against time (baseline= before the sleeve procedure, thereafter yearly).
- Identifying the rate of clinical dyspepsia in the whole cohort (n=20435) as plotted against time (baseline= before the sleeve procedure, thereafter yearly).
- Identifying the Incidence of initial suboptimal clinical response vs recurrent weight gain in the whole cohort versus the group of patients converted regardless of indication for conversion.
- Estimate eligibility for a second revisional procedure in the total cohort due to either suboptimal weight loss outcomes/recurrence of comorbidities or dyspepsia.
- Identifying potential predictors for incidence of clinical dyspepsia ("Time from sleeve operation to dyspepsia is the outcome") leading to conversion (use of PPI before sleeve, dyspepsia before sleeve, hiatal hernia before sleeve, age, sex, BMI, smoking status, and clinical operating unit (high-volume vs low-volume). Nb! Dyspepsia is noted yearly (column HQ: year one; IV: year two etc).
Study Design The study is a retrospective study on prospectively collected data from the national registry on bariatric surgery, SOReg, where data on metabolic and bariatric surgeries in Sweden are collected.
The cohort will be all primary sleeve operations in Sweden performed during the years 2012 to 2024, with a total of n=20.435 patients. TThe design will be register-based cohort study, with a maximum follow-up time up to 15 years.
Study outcomes and predictors in weight strata (5 BMI points each)
a Conversion: Prevalence of conversion of SG to another procedure: RYGB, SASI, Duodenal switch, or a two-stage planned procedure (first SG and then later another like the DS). The data from the excel file should be held up against the total number of sleeve procedures in the same time period to assess the true prevalence.
b Procedural factors: These include operative time, Length of Stay (LOS), early complications (leaks, bleeding, reoperation, non-operative intervention, readmission, cardiac events, pneumonia, thromboembolic complications, wound infection, sepsis, death), and late complications (bowel obstruction, marginal ulcers, abdominal pain, laparoscopy with no pathology, malnutrition, and malabsorption)
c Predictors for all complications en bloc, for mortality, for early vs late complications, and then for all complications individually. Potential variables to be evaluated: Height, weight, sex, BMI, medical comorbidities one-by-one, smoking status, operative time, prior thromboembolic complications, operating unit (high-volume vs low-volume as defined by the number of procedures the operating units perform annually; this information is not available from the excel file, but I suggest preliminarily that the number of complications are stratified according to the respective operating units)
e Predictors for resolution of symptoms: intestinal limb length (alimentary limb, biliopancreatic limb and common channel), crura plasty (posterior vs anterior), other concomitant reflux procedures, operating unit (high-volume vs low-volume).
f Weight loss outcomes weight in kg, body mass index (BMI), percent of total weight loss (%TWL), percent excess weight loss (%EWL), and delta BMI (ΔBMI). The above mentioned are calculated as follows:
- %TWL = (Initial Weight - Postop Weight)/ (Initial Weight x 100)
- %EWL = (Initial Weight - (Postop Weight) / (Initial Weight - Ideal Weight)
- ΔBMI = (Initial BMI - Postop BMI) (Ideal weight is defined as the weight in kg that corresponds to a BMI of 25 kg/m2) g Medical comorbidities Diabetes mellitus (DM), Hypertension (HT), Dyslipidaemia (DL), and Obstructive Sleep Apnoea (OSA) i Weight loss outcomes (BMI, kg, EWL and TWL) should be assessed for Group 1 as a whole and also when dichotomized according to the following two groups: I) Recurrent weight gain (previously called poor responders) II) Initial suboptimal clinical response (previously called non-responders). j Eligibility here is defined as having a BMI ≥ 35 kg/m2 or BMI ≥ 30 kg/m2 along with a recurrence/presence of obesity-associated medical comorbidities (DM, HT, DL, OSA, Arthritis).
Predictors of resolution of comorbidities Variables to be considered potential predictors: preoperative weight and BMI, sex, age, smoking status, distance from angle of Hiss, distance to pylorus, numbers of staplers used, summated length of staplers, operative time.
**Complications: Peri-operative complications: Injury to sleen, bowel perforation, other complication and bleeding (100-499, 500-1500, and >1500 ml).
Complications within 6 weeks: Leakage, Bleeding Abcess/deep infection, Wound dehiscence, Other WOund complication, bowel obstruction/paralysis, Port related complication, Stricture, Ulcer, Cardio-vascular complication, DVT/PE, Pulmonary complication, Unrinary tract infection, Other complication, and Severity of complications according to Clavien Dindo classification.
Complications until 1y:
Complications can then be analysed yearly according to the data available in the spread sheet.
Reasons for conversion to another bariatric procedure and relief of problems:
Group 1: Symptoms: Clinical GERD, dyspepsia, dysphagia, stricture or obstruction, nausea or vomiting, staple line leak, hiatal hernia, intrathoracic migration of the sleeve or anything else that can be classified as complications after a sleeve gastrectomy.
Group 2: Suboptimal weight loss: Initial suboptimal clinical response and recurrent weight gain, as well as recurrence of obesity-associated medical comorbidities or persistent obesity-associated medical comorbidities.
Statistical analyses
Summary tables (descriptive statistics and frequency tables) will be provided for all baseline variables, outcome variables, and safety variables, as appropriate. Continuous variables will be summarized with descriptive statistics (n, mean, standard deviation, range, and median). Frequency counts and percentage of subjects within each category will be provided for categorical data.
For the primary aim, time to first ever conversion will be evaluated with the Kaplan-Meier estimates and Cox proportional hazards models. Time to event will be calculated as the time difference between the index operation with SG to another procedure. Persons without another procedure will be censored at the the time point when the register was complete. From the Kaplan-Meier and Cox-models, cumulative incidence of proportion converting will be evaluated since the time of primary SG operation.
For persons with symptoms leading to conversion, resolution of these symptoms will be evaluated at x months/years since conversion. Time-to-event or logistic regression models.
For persons with suboptimal weight loss as reason for conversion, weight loss outcomes will be evaluated.
Proportions with resolution of co-morbidities and incidence of complications will be analysed with time-to-event/logistic regression model.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 15 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with severe obesity undergoing primary sleeve gastrectomy in Sweden | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients in Sweden operated with the bariatric techniqu sleeve gastrectomy between 1 Jan 2012 and 31 of Oct 2024
Key inclusion criteria (2 listed)
- All patients undergoing sleeve gastrectomy in Sweden from 1 Jan 2012
- Being registered in the national quality register SOReg
Key exclusion criteria (2 listed)
- Previously undergone bariatric surgery
- Sleeve gastrectomy as a planned two staged intervention
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Weight loss
Time frame: 15 years
BMI loss in strata of 5 BMI units
Weight loss in BMI strata
Time frame: 15 years
Weight loss
Time frame: Up to 15 years
Various definitions of weight loss over time
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Dec 2025.
- Individual participant dataSharing planned: No. Ongoing further investigations in the dataset
Related trials for Severe Obesity
Not yet recruitingObservational study
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
Abdominal Aortic Aneurysm, Morbid Obesity
Not yet recruitingObservational study
Evaluating Metabolic Health in Individuals With Extreme Obesity
BMI>40
RecruitingPhase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Crohn's Disease, Obesity or Overweight
RecruitingPhase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ulcerative Colitis, Obesity or Overweight
Active, not recruitingPhase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Torsten Olbers, MD, Professor study chair
Linköpings universitet, 202100-3096
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Severe Obesity and Sleeve Gastrectomy, run by Linkoeping University at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Weight loss (time frame: 15 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Dec 2025.